Please use this identifier to cite or link to this item:
Scopus Web of ScienceĀ® Altmetric
Type: Journal article
Title: Post-inhalation bronchoconstriction by beclomethasone dipropionate: A comparison of two different CFC propellant formulations in asthmatics
Author: Ruffin, R.
Campbell, D.
Chia, M.
Citation: Respirology, 2000; 5(2):125-131
Publisher: Blackwell Publishing Asia
Issue Date: 2000
ISSN: 1323-7799
Statement of
Ruffin, Richard E. ; Campbell, Donald A. ; Chia, Mon M.
Abstract: <h4>Objective</h4>To assess the change in bronchial response to cumulative doses from two beclomethasone dipropionate metered-dose inhalers (MDI), each using chlorofluorocarbon (CFC) propellants, in asthma patients previously showing falls in forced expiratory volume in 1 s (FEV1) shortly after exposure to beclomethasone MDI.<h4>Methodology</h4>A total of 18 patients were randomized to a single-blind, three-period cross-over treatment regimen, whereby each was administered increasing doses of control mixture (containing surfactant and CFC propellants) or beclomethasone, formulated as either Becloforte or Respocort (250-1000 microg per dose; cumulative dose 2000 microg). Bronchial response was measured by comparison of FEV1 values pre- and post-inhalation.<h4>Results</h4>Respocort formulation produced the least post-dose mean maximum reduction in FEV1 (0.36 +/- 0.17 L; 14.3 +/- 7.2% of baseline FEV1), while the reduction caused by the control was similar (0.40 +/- 0.18 L; 16.2 +/- 9.9% of baseline FEV1). Becloforte produced a significantly greater maximum reduction in FEV1 than Respocort (0.55 +/- 0.32 L, P = 0.003; 22.0 +/- 15.3% of baseline FEV1, P = 0.005). No serious adverse events were reported, but four patients experienced falls in FEV1 of greater than 15% (three on Becloforte, one using the control).<h4>Conclusion</h4>The incidence of falls in FEV1 following use of beclomethasone MDI was low and generally not serious even in a selected population. The Becloforte preparation produced significantly more post-dose bronchoconstriction than the Respocort formulation, perhaps because of differences in the composition of the surfactant and/or CFC propellant mixtures used to formulate each of the aerosols.
Keywords: Humans
Chlorofluorocarbons, Methane
Anti-Inflammatory Agents
Anti-Asthmatic Agents
Surface-Active Agents
Forced Expiratory Volume
Administration, Inhalation
Administration, Topical
Cross-Over Studies
Single-Blind Method
Middle Aged
DOI: 10.1046/j.1440-1843.2000.00238.x
Published version:
Appears in Collections:Aurora harvest 4
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.